NICOLE MARK: Open Payments
NPI 1609428598 · SAN DIEGO, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,519 in 52 payments from 7 companies in 2025. Trend: 2023 $1,141 · 2024 $987 · 2025 $1,519
Food & beverage: $1,519
| Company | Payments | Amount |
|---|---|---|
| GlaxoSmithKline, LLC. | 13 | $464 |
| Merck Sharp & Dohme LLC | 16 | $406 |
| AstraZeneca Pharmaceuticals LP | 12 | $241 |
| Eisai Inc. | 7 | $179 |
| Axsome Therapeutics, Inc. | 1 | $140 |
| Caris MPI, Inc. | 2 | $54 |
| ABBVIE INC. | 1 | $35 |
Products named: JEMPERLI, LYNPARZA, Lenvima, Symbravo, KEYTRUDA, MI CANCER SEEK, ELAHERE.
Industry payments across CA — which companies pay providers there.
